Quantcast
Last updated on April 18, 2014 at 1:21 EDT

Latest Nitazoxanide Stories

2014-03-06 08:31:51

MOSCOW, March 6, 2014 /PRNewswire/ -- A group of 48 patients infected with the hepatitis B virus (HBV) have been enrolled in the phase IIa clinical trial of Myrcludex B by Russian biotech company Hepatera Ltd. [http://www.hepatera.ru/?ln=en ] Hepatera is financed by Maxwell Biotech Venture Fund [http://www.maxwellbiotech.com ], set up with the participation of RVC [http://www.rusventure.ru/en ] - Russia's government fund of venture capital funds. Hepatera was...

2013-08-07 12:27:36

MUMBAI and BALTIMORE, August 7, 2013 /PRNewswire/ -- Announces Acquisition of Exclusive US Rights to Alinia(R) for Oral Suspension Pharmaceutical Major, Lupin Ltd. and its US subsidiary, Lupin Pharmaceuticals Inc. (collectively Lupin) announced today that it has signed a strategic licensing agreement with US pharmaceutical company Romark Laboratories, L.C. (Romark) which grants Lupin exclusive rights to promote, distribute and market Alinia(R) (nitazoxanide) for Oral...

2013-08-07 12:26:28

Lupin Acquires Exclusive License to Promote and Distribute Alinia for Oral Suspension in the United States using its Pediatric-Focused Sales Force TAMPA, Fla., Aug. 7, 2013 /PRNewswire/ -- Romark Laboratories announced that it has entered into a strategic agreement with Lupin Limited and its subsidiaries (collectively Lupin) designed to expand promotion and distribution efforts related to its Alinia(®) (nitazoxanide) for Oral Suspension, 100 mg/5 mL. Under the agreement, Lupin...

2013-04-18 08:32:35

Global Phase 3 Clinical Trial to Study NT-300 for Treatment of Acute Uncomplicated Influenza TAMPA, Fla., April 18, 2013 /PRNewswire/ -- Romark Laboratories announced that it has begun enrolling patients in a global Phase 3 clinical trial of NT-300 (nitazoxanide) for treatment of acute uncomplicated influenza. (Logo: http://photos.prnewswire.com/prnh/20100201/FL47022LOGO ) The Phase 3 clinical trial has been initiated in the United States, will continue in Australia and New...

2013-02-28 16:27:49

$44 Million Contract with U.S. Department of Health and Human Services to Fund Completion of Clinical Development and Preparation for Submission of New Drug Application for NT-300 TAMPA, Fla., Feb. 28, 2013 /PRNewswire/ -- Romark Laboratories has been awarded a contract with the U.S. Department of Health and Human Services (HHS) to complete the advanced development of NT-300 (nitazoxanide) as a treatment of acute uncomplicated influenza. The value of the cost plus fixed-fee contract...

2013-01-31 15:18:11

People with hepatitis C and chronic liver disease who relapsed or failed to respond to initial treatment are unlikely to improve on interferon retreatment. In fact, they may face an increased risk of dying sooner, and are likely to experience a variety of adverse effects, according to an updated systematic review published in The Cochrane Library. Hepatitis C affects around 170 million people worldwide. In some cases, infection leads to chronic liver disease, liver failure or liver cancer,...

Drug-resistant Tuberculosis Killed By Old Pain Drug
2012-09-11 09:08:37

April Flowers for redOrbit.com - Your Universe Online Researchers at Weill Cornell Medical College have found that an off-patent anti-inflammatory drug that costs about two cents for a daily dose can also kill both replicating and non-replicating drug-resistant tuberculosis in the laboratory. Few currently approved TB drugs can do this, and resistance to those is spreading. Reported in the Proceedings of the National Academy of Sciences, the study points to a potential new therapy for...

2011-10-21 09:13:00

TAMPA, Fla., Oct. 21, 2011 /PRNewswire/ -- Romark Laboratories announced that results of a large Phase 2B-3 US clinical trial of its new flu drug, NT-300 (nitazoxanide), will be presented as an oral late-breaking communication at the 49th Annual Meeting of the Infectious Diseases Society of America (IDSA) being held in Boston, October 20-23, 2011. (Logo: http://photos.prnewswire.com/prnh/20100201/FL47022LOGO ) The clinical trial enrolled 624 patients at 74 outpatient primary care...

2010-11-01 08:38:00

TAMPA, Fla., Nov. 1, 2010 /PRNewswire/ -- Romark Laboratories announced that data from studies of nitazoxanide in hepatitis C are being presented at the 61st Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), also known as The Liver Meeting® in Boston, October 30 - November 2, 2010. (Logo: http://www.newscom.com/cgi-bin/prnh/20100201/FL47022LOGO ) (Logo: http://photos.prnewswire.com/prnh/20100201/FL47022LOGO ) "The data presented at...

2010-10-21 07:00:00

TAMPA, Fla., Oct. 21 /PRNewswire/ -- Romark Laboratories, L.C. and Intercell AG (VSE; "ICLL") today announced plans to commence clinical trials of Romark's antiviral drug, nitazoxanide, in combination with Intercell's investigational therapeutic hepatitis C virus (HCV) vaccine, IC41, during the first half of 2011. (Logo: http://photos.prnewswire.com/prnh/20100201/FL47022LOGO ) (Logo: http://www.newscom.com/cgi-bin/prnh/20100201/FL47022LOGO ) Intercell's vaccine candidate has demonstrated...